Morgan Stanley Amicus Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,215,331 shares of FOLD stock, worth $40.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,215,331

Previous 4,992,727 15.57%

Holding current value

$40.8 Million

Previous $49.5 Million 9.1%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$9.55 - $12.09 $7.42 Million - $9.4 Million	-777,396 Reduced 15.57%	4,215,331 $45 Million
Q2 2024 Oct 17, 2024	SELL	$9.04 - $11.75 $42.6 Million - $55.4 Million	-4,712,121 Reduced 48.55%	4,992,727 $49.5 Million
Q2 2024 Aug 14, 2024	SELL	$9.04 - $11.75 $42.6 Million - $55.4 Million	-4,712,121 Reduced 48.55%	4,992,727 $49.5 Million
Q1 2024 Oct 17, 2024	BUY	$11.43 - $14.24 $53.9 Million - $67.1 Million	4,712,121 Added 94.38%	9,704,848 $114 Million
Q1 2024 Aug 16, 2024	SELL	$11.43 - $14.24 $41.4 Million - $51.6 Million	-3,623,049 Reduced 27.18%	9,704,848 $114 Million
Q1 2024 May 15, 2024	SELL	$11.43 - $14.24 $41.4 Million - $51.6 Million	-3,623,049 Reduced 27.18%	9,704,848 $114 Million
Q4 2023 Aug 16, 2024	BUY	$9.97 - $14.52 $83.1 Million - $121 Million	8,335,170 Added 166.95%	13,327,897 $189 Million
Q4 2023 Feb 13, 2024	BUY	$9.97 - $14.52 $25.7 Million - $37.5 Million	2,579,205 Added 24.0%	13,327,897 $189 Million
Q3 2023 Nov 15, 2023	SELL	$11.78 - $13.86 $27.2 Million - $32 Million	-2,312,116 Reduced 17.7%	10,748,692 $131 Million
Q2 2023 Aug 14, 2023	SELL	$10.72 - $13.3 $36.9 Million - $45.8 Million	-3,440,101 Reduced 20.85%	13,060,808 $164 Million
Q1 2023 May 15, 2023	SELL	$10.91 - $13.54 $14.6 Million - $18.1 Million	-1,338,445 Reduced 7.5%	16,500,909 $183 Million
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $6.49 Million - $8.33 Million	655,841 Added 3.82%	17,839,354 $218 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $11.1 Million - $14.4 Million	-1,130,067 Reduced 6.17%	17,183,513 $179 Million
Q2 2022 Oct 27, 2022	BUY	$6.23 - $11.12 $6.8 Million - $12.1 Million	1,092,228 Added 6.34%	18,313,580 $197 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $11.12 $6.8 Million - $12.1 Million	1,092,228 Added 6.34%	18,313,580 $197 Million
Q1 2022 Oct 27, 2022	SELL	$7.89 - $12.48 $8.62 Million - $13.6 Million	-1,092,228 Reduced 5.96%	17,221,352 $163 Million
Q1 2022 May 13, 2022	BUY	$7.89 - $12.48 $28.3 Million - $44.7 Million	3,580,927 Added 26.25%	17,221,352 $163 Million
Q4 2021 Feb 14, 2022	BUY	$9.82 - $12.44 $19.2 Million - $24.3 Million	1,952,036 Added 16.7%	13,640,425 $158 Million
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $102 Million - $138 Million	11,688,389 New	11,688,389 $112 Million

Others Institutions Holding FOLD

# of Institutions

311

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.72B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account